Hhex regulates Kit to promote radioresistance of self-renewing thymocytes in Lmo2-transgenic mice

Benjamin Shields, R. Alserihi, C. Nasa, C. Bogue, W. S. Alexander, M. P. McCormack

Research output: Contribution to journalArticleResearchpeer-review

8 Citations (Scopus)

Abstract

Lmo2 is an oncogenic transcription factor that is frequently overexpressed in T-cell acute leukemias, in particular poor prognosis early T-cell precursor-like (ETP-) acute lymphoblastic leukemia (ALL). The primary effect of Lmo2 is to cause self-renewal of developing CD4 - CD8 - (double negative, DN) T cells in the thymus, leading to serially transplantable thymocytes that eventually give rise to leukemia. These self-renewing thymocytes are intrinsically radioresistant implying that they may be a source of leukemia relapse after therapy. The homeobox transcription factor, Hhex, is highly upregulated in Lmo2-transgenic thymocytes and can phenocopy Lmo2 in inducing thymocyte self-renewal, implying that Hhex may be a key component of the Lmo2-induced self-renewal program. To test this, we conditionally deleted Hhex in the thymi of Lmo2-transgenic mice. Surprisingly, this did not prevent accumulation of DN thymocytes, nor alter the rate of overt leukemia development. However, deletion of Hhex abolished the transplantation capacity of Lmo2-transgenic thymocytes and overcame their radioresistance. We found that Hhex regulates Kit expression in Lmo2-transgenic thymocytes and that abrogation of Kit signaling phenocopied loss of Hhex in abolishing the transplantation capacity and radioresistance of these cells. Thus, targeting the Kit signaling pathway may facilitate the eradication of leukemia-initiating cells in immature T-cell leukemias in which it is expressed.

Original languageEnglish
Pages (from-to)927-938
Number of pages12
JournalLeukemia
Volume29
Issue number4
DOIs
Publication statusPublished - 15 Apr 2015
Externally publishedYes

Cite this

Shields, Benjamin ; Alserihi, R. ; Nasa, C. ; Bogue, C. ; Alexander, W. S. ; McCormack, M. P. / Hhex regulates Kit to promote radioresistance of self-renewing thymocytes in Lmo2-transgenic mice. In: Leukemia. 2015 ; Vol. 29, No. 4. pp. 927-938.
@article{a7c0c2f4cf2d4d40a12c00d8f0dc3fd5,
title = "Hhex regulates Kit to promote radioresistance of self-renewing thymocytes in Lmo2-transgenic mice",
abstract = "Lmo2 is an oncogenic transcription factor that is frequently overexpressed in T-cell acute leukemias, in particular poor prognosis early T-cell precursor-like (ETP-) acute lymphoblastic leukemia (ALL). The primary effect of Lmo2 is to cause self-renewal of developing CD4 - CD8 - (double negative, DN) T cells in the thymus, leading to serially transplantable thymocytes that eventually give rise to leukemia. These self-renewing thymocytes are intrinsically radioresistant implying that they may be a source of leukemia relapse after therapy. The homeobox transcription factor, Hhex, is highly upregulated in Lmo2-transgenic thymocytes and can phenocopy Lmo2 in inducing thymocyte self-renewal, implying that Hhex may be a key component of the Lmo2-induced self-renewal program. To test this, we conditionally deleted Hhex in the thymi of Lmo2-transgenic mice. Surprisingly, this did not prevent accumulation of DN thymocytes, nor alter the rate of overt leukemia development. However, deletion of Hhex abolished the transplantation capacity of Lmo2-transgenic thymocytes and overcame their radioresistance. We found that Hhex regulates Kit expression in Lmo2-transgenic thymocytes and that abrogation of Kit signaling phenocopied loss of Hhex in abolishing the transplantation capacity and radioresistance of these cells. Thus, targeting the Kit signaling pathway may facilitate the eradication of leukemia-initiating cells in immature T-cell leukemias in which it is expressed.",
author = "Benjamin Shields and R. Alserihi and C. Nasa and C. Bogue and Alexander, {W. S.} and McCormack, {M. P.}",
year = "2015",
month = "4",
day = "15",
doi = "10.1038/leu.2014.292",
language = "English",
volume = "29",
pages = "927--938",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Macmillan Publishers",
number = "4",

}

Hhex regulates Kit to promote radioresistance of self-renewing thymocytes in Lmo2-transgenic mice. / Shields, Benjamin; Alserihi, R.; Nasa, C.; Bogue, C.; Alexander, W. S.; McCormack, M. P.

In: Leukemia, Vol. 29, No. 4, 15.04.2015, p. 927-938.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Hhex regulates Kit to promote radioresistance of self-renewing thymocytes in Lmo2-transgenic mice

AU - Shields, Benjamin

AU - Alserihi, R.

AU - Nasa, C.

AU - Bogue, C.

AU - Alexander, W. S.

AU - McCormack, M. P.

PY - 2015/4/15

Y1 - 2015/4/15

N2 - Lmo2 is an oncogenic transcription factor that is frequently overexpressed in T-cell acute leukemias, in particular poor prognosis early T-cell precursor-like (ETP-) acute lymphoblastic leukemia (ALL). The primary effect of Lmo2 is to cause self-renewal of developing CD4 - CD8 - (double negative, DN) T cells in the thymus, leading to serially transplantable thymocytes that eventually give rise to leukemia. These self-renewing thymocytes are intrinsically radioresistant implying that they may be a source of leukemia relapse after therapy. The homeobox transcription factor, Hhex, is highly upregulated in Lmo2-transgenic thymocytes and can phenocopy Lmo2 in inducing thymocyte self-renewal, implying that Hhex may be a key component of the Lmo2-induced self-renewal program. To test this, we conditionally deleted Hhex in the thymi of Lmo2-transgenic mice. Surprisingly, this did not prevent accumulation of DN thymocytes, nor alter the rate of overt leukemia development. However, deletion of Hhex abolished the transplantation capacity of Lmo2-transgenic thymocytes and overcame their radioresistance. We found that Hhex regulates Kit expression in Lmo2-transgenic thymocytes and that abrogation of Kit signaling phenocopied loss of Hhex in abolishing the transplantation capacity and radioresistance of these cells. Thus, targeting the Kit signaling pathway may facilitate the eradication of leukemia-initiating cells in immature T-cell leukemias in which it is expressed.

AB - Lmo2 is an oncogenic transcription factor that is frequently overexpressed in T-cell acute leukemias, in particular poor prognosis early T-cell precursor-like (ETP-) acute lymphoblastic leukemia (ALL). The primary effect of Lmo2 is to cause self-renewal of developing CD4 - CD8 - (double negative, DN) T cells in the thymus, leading to serially transplantable thymocytes that eventually give rise to leukemia. These self-renewing thymocytes are intrinsically radioresistant implying that they may be a source of leukemia relapse after therapy. The homeobox transcription factor, Hhex, is highly upregulated in Lmo2-transgenic thymocytes and can phenocopy Lmo2 in inducing thymocyte self-renewal, implying that Hhex may be a key component of the Lmo2-induced self-renewal program. To test this, we conditionally deleted Hhex in the thymi of Lmo2-transgenic mice. Surprisingly, this did not prevent accumulation of DN thymocytes, nor alter the rate of overt leukemia development. However, deletion of Hhex abolished the transplantation capacity of Lmo2-transgenic thymocytes and overcame their radioresistance. We found that Hhex regulates Kit expression in Lmo2-transgenic thymocytes and that abrogation of Kit signaling phenocopied loss of Hhex in abolishing the transplantation capacity and radioresistance of these cells. Thus, targeting the Kit signaling pathway may facilitate the eradication of leukemia-initiating cells in immature T-cell leukemias in which it is expressed.

UR - http://www.scopus.com/inward/record.url?scp=84927584759&partnerID=8YFLogxK

U2 - 10.1038/leu.2014.292

DO - 10.1038/leu.2014.292

M3 - Article

VL - 29

SP - 927

EP - 938

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 4

ER -